Tag Archives: Frost & Sullivan

Indonesia “Most Promising” Emerging Market in 2015

Indonesia is expected to be the most promising market for pharma next year, thanks to its new healthcare insurance scheme Jaminan Kesehatan Nasional (JKN), according to Reenita Das, partner and senior vice president of Healthcare & Life Sciences at Frost & Sullivan.
Posted in Emerging Markets, Global, Op-Ed | Also tagged , , , , | Leave a comment

Rise in IPOs Eases Pharma's Investment Woes

Private equity and venture capital (PEVC) deal activity decreased from 1063 in 2010 to 480 in 2013, according to a new Frost & Sullivan report. And the pharma, biotech and healthcare equipment sectors experienced a much sharper decline in investor interest than the healthcare technology and provider segments, the report adds. But there is a […]
Posted in Biotech, Deals, Global, healthcare | Also tagged , , , , | Leave a comment

Global Biosimilars Market to Soar to $24 Billion by 2019

Frost & Sullivan: Strong Pipeline of Monoclonal Antibodies (mAbs) Biosimilars in the US and Europe Lends Impetus to Global Market The market is expected to soar from $1.2 billion of 2013 to $24 billion in 2019 LONDON – 29th January 2014 – The imminent entry of several companies, including big pharma, small biotech and generic […]
Posted in Biotech, Europe, Global, Strategy | Also tagged , | 1 Comment

BRIC Opportunities 2014

While the tide has been turning for pharma in the BRIC markets, they will continue to be important but only if the industry has learnt the hard lessons of the last few years. Speaking to Pharm Exec for the 2014 Industry Outlook, Reenita Das, Partner at Frost & Sullivan, says its now more important than […]
Posted in Global, Strategy | Also tagged , , , , , , , | Leave a comment

FDA Push for TRF Therapies Will 'Disrupt Pain Market'

FDA’s push for abuse-resistant opioid formulations will disrupt the pain market, say analysts Frost & Sullivan. The opioid market is currently dominated by non-tamper resistant formulations (TRFs), but FDA’s promotion of TRF therapies “could well result in the departure of non-TRF therapies from the market and shake up its structure.” Unless FDA mandates TRF therapies, […]
Posted in FDA, Safety, Strategy | Also tagged , , , | 1 Comment
  • Categories

  • Meta